Q2 Revenue Jump and Raised Guidance Can't Mask Weakening Firm Backlog and Dilution

What happened

Planet Labs Q2 FY2027 revenue jumped 58% to $116.1 million, GAAP gross margin reached 57%, adjusted EBITDA turned positive at $13.9 million, and management raised full-year guidance, yet the stock sold off after Q3 revenue was guided down to $101–$105 million with an expected adjusted EBITDA loss. A Seeking Alpha article titled 'The Sell-Off Masks A Much Stronger Business' argues the defense/intelligence-heavy mix and over $400 million expected 12-month backlog conversion support future growth. However, filings show that remaining performance obligations fell to $753.1 million from $852.4 million and backlog fell to $814.9 million from $900.4 million, meaning near-term conversion rose only because total contracted value shrank. The company also raised FY2027 capex guidance to $100–$115 million from $80–$95 million and issued about $120 million of stock via its ATM at an average price of $31.95, lifting diluted shares to 359.6 million from 304.1 million a year earlier. Revenue momentum and sovereign demand are real, but firm per-share value is not yet being replenished at the same pace.

Implication

Investors should separate strong revenue growth from per-share value creation because the company is consuming equity and capital faster than it is adding firm contracted value. The bull case hinges on Q3 landing near the high end of guidance and new sovereign awards replenishing RPO, while the bear case sees continued lumpiness and rising capex eroding the margin of safety. At around $16, the stock trades close to the base-case fair value of $17, so upside is limited unless the bull scenario materializes; a better entry appears near $14. Watch for any additional ATM issuance or further decline in RPO/backlog in the next two quarterly filings, as those would undermine the thesis. Conversely, if backlog stabilizes and no more dilution occurs, the rating could improve, but until then a WAIT discipline with defined trim levels above $21 is prudent.

Thesis delta

The new article reiterates the existing bullish narrative around government demand but does not address the deterioration in firm contracted value or the dilutive financing. No change to the master thesis: Planet's moat is real, but buying today offers insufficient edge because the stock already prices in sovereign growth while RPO and backlog are declining and share count is rising. The confirmation of raised capex and ATM usage strengthens the cautious stance rather than shifting it.